Welcome - Register - Login - Help/FAQ - 0 items

Search Enter keywords, a title or a report id number below. In All Categories --------------------- Telecom & Computing Business & Finance Mfg & Construction Pharma & Healthcare Consumer & Retail Gov & Public Sector Energy & Transport Country Reports Company Reports --------------------- Transcripts Advanced      Select a currency for use throughout the site Australia Dollars Canada Dollars Euro Japan Yen Sweden Kroner Switzerland Francs UK Pounds US Dollars Search Results Your Search for 'Angiogenesis Inhibitors - State-of-the-Science and Strategic Opportunities' returned 53 results - Page 1 of 3   Sort by    Date Published ASC Date Published DESC Report Price ASC Report Price DESC Rank ASC Rank DESC   Sorted by Rank Top-Bottom Angiogenesis Inhibitors and Stimulators - Global Strategic Business Report   Global Industry Analysts, Inc., Feb 2011, Pages: 682 Angiogenesis Inhibitors and Stimulators - Global Strategic Business Report This report analyzes the worldwide markets for Angiogenesis Inhibitors and Stimulators in US$ Million by the following Triple Analysis: Leukemia, Angiogenesis and Protein Kinase Inhibitors   Bioseeker, May 2012, Pages: 5791 Triple Analysis: Leukemia, Angiogenesis and Protein Kinase Inhibitors This triple analysis focuses on cancer drug development strategies in Leukemia and by the two mechanism/target/effect areas of Triple Analysis: Lymphoma, Angiogenesis and Protein Kinase Inhibitors   Bioseeker, May 2012, Pages: 5598 Triple Analysis: Lymphoma, Angiogenesis and Protein Kinase Inhibitors This triple analysis focuses on cancer drug development strategies in Lymphoma and by the two mechanism/target/effect areas of Triple Analysis: Breast Cancer, Angiogenesis and Protein Kinase Inhibitors   Bioseeker, May 2012, Pages: 5557 Triple Analysis: Breast Cancer, Angiogenesis and Protein Kinase Inhibitors This triple analysis focuses on cancer drug development strategies in Breast Cancer and by the two mechanism/target/effect Triple Analysis: Angiogenesis, Protein Kinase Inhibitors and Antibodies   Bioseeker, May 2012, Pages: 6588 Triple Analysis: Angiogenesis, Protein Kinase Inhibitors and Antibodies This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Angiogenesis and Triple Analysis: Angiogenesis, Protein Kinase Inhibitors and Peptides   Bioseeker, May 2012, Pages: 5550 Triple Analysis: Angiogenesis, Protein Kinase Inhibitors and Peptides This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Angiogenesis and Triple Analysis: Lung Cancer, Angiogenesis and Protein Kinase Inhibitors   Bioseeker, May 2012, Pages: 5967 Triple Analysis: Lung Cancer, Angiogenesis and Protein Kinase Inhibitors This triple analysis focuses on cancer drug development strategies in Lung Cancer and by the two mechanism/target/effect areas Triple Analysis: Pancreatic Cancer, Angiogenesis and Protein Kinase Inhibitors   Bioseeker, May 2012, Pages: 5747 Triple Analysis: Pancreatic Cancer, Angiogenesis and Protein Kinase Inhibitors This triple analysis focuses on cancer drug development strategies in Pancreatic Cancer and by the two mechanism/target Triple Analysis: Colorectal Cancer, Angiogenesis and Protein Kinase Inhibitors   Bioseeker, May 2012, Pages: 5700 Triple Analysis: Colorectal Cancer, Angiogenesis and Protein Kinase Inhibitors This triple analysis focuses on cancer drug development strategies in Colorectal Cancer and by the two mechanism/target Triple Analysis: Apoptosis, Angiogenesis and Protein Kinase Inhibitors   Bioseeker, May 2012, Pages: 6261 Triple Analysis: Apoptosis, Angiogenesis and Protein Kinase Inhibitors This triple analysis focuses on cancer drug development strategies by mechanism/target/effect of Apoptosis, Angiogenesis and Triple Analysis: Melanoma, Angiogenesis and Protein Kinase Inhibitors   Bioseeker, May 2012, Pages: 5421 Triple Analysis: Melanoma, Angiogenesis and Protein Kinase Inhibitors This triple analysis focuses on cancer drug development strategies in Melanoma and by the two mechanism/target/effect areas of Triple Analysis: Prostate Cancer, Angiogenesis and Protein Kinase Inhibitors   Bioseeker, May 2012, Pages: 5482 Triple Analysis: Prostate Cancer, Angiogenesis and Protein Kinase Inhibitors This triple analysis focuses on cancer drug development strategies in Prostate Cancer and by the two mechanism/target Triple Analysis: Angiogenesis, Cancer Vaccines and Protein Kinase Inhibitors   Bioseeker, May 2012, Pages: 5303 Triple Analysis: Angiogenesis, Cancer Vaccines and Protein Kinase Inhibitors This triple analysis focuses on cancer drug development strategies by mechanism/target/effect of Angiogenesis, Cancer Challenges and Opportunities in Developing Chemopreventive Agents   Decision Resources, Inc., Nov 2007, Pages: 29 Chemopreventive Agent Development FDA-Approved Agents EGFR Inhibitors HMG-CoA Reductase Inhibitors Angiogenesis Inhibitors Matrix Metalloproteinases Combination Therapies Strategic Alliances with Nutraceutical Histone Deacetylase inhibitors   Lead Discovery, May 2005 key issues & conclusions - The field of HDAC inhibitors has been driven by their ability to modulate transcriptional activity. As a result, this therapeutic class is able to block angiogenesis and cell The Complete Guide to Targeted Therapies in Oncology: A World Review   Bioseeker, Dec 2006, Pages: 550 report - Understand the clinical and strategic challenges to the commercialization of aix major targeting strategies in oncology - Assess opportunities and risks for the continued development of targeting U.S. Emerging Cancer Therapeutics Markets   Frost & Sullivan, Jan 1999 and Development Pipeline - Market Engineering Research for the U.S. Market for Angiogenesis Inhibitors - Strategic Analysis and Forecasts of the Total Market - Competitive Structure Pipeline Insight: Small Molecule Targeted Cancer Therapies - New targets set to drive growth   Datamonitor, April 2010, Pages: 243 products -Identify licensing opportunities based on company portfolio and market needs Overview Catalyst Summary Executive Summary Strategic scoping and focus Datamonitor insight into the small Competitive Outlook on Antiangiogenesis and Vascular Targeting in Oncology   Bioseeker, Oct 2006, Pages: 125 formulations, we identify that angiogenesis inhibitors will be the most promising for future treatment of prostate cancer. Key reasons to read this report - Understand the clinical and strategic challenges to The Targeted Cancer Therapies Pipeline: A Strategic Review   Decision Resources, Inc., Dec 2009, Pages: 34 The Targeted Cancer Therapies Pipeline: A Strategic Review The current flurry of research into the development of new drugs against novel cancer targets is unprecedented. Many pharmaceutical and Results:  First -   Prev -   1 -   2 -   3 -   Next -   Last

		For enquiries please call us on:   +353-1-415-1241 (GMT Office Hours)   1-917-300-0470 (EST Office Hours)

All rights reserved. © Copyright 2012 Research and Markets2    Terms and conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network